Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Asensus Surgical reports Q1 loss but eyes stability through acquisition

Asensus Surgical's Q1 2024 performance showed a significant net loss, but the potential acquisition by KARL STORZ offers financial stability. The company aims to sustain operations into Q3 2024 and beyond with available cash and additional financing. Ongoing initiatives focus on advancing surgical systems and expanding global programs.

Asensus Surgical reports Q2 losses, merger vote adjourned

Asensus Surgical faces financial struggles with a significant net loss and liquidity concerns.
The proposed merger with Karl Storz offers a potential strategic advantage but hinges on stockholder approval.
Addressing operational inefficiencies and investor engagement are critical for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

Asensus Surgical (NYSEMKT: ASXC ) stock is rising higher on Thursday as investors react to news of a collaboration with Nvidia (NASDAQ: NVDA ). The big announcement here is Asensus Surgical teaming up with Nvidia to accelerate the development of its Intelligent Surgical Unit (ISU).

Why Is Asensus Surgical (ASXC) Stock Up 18% Today?

Novo Integrated Sciences, Inc.

Synaptogenix

Penny stocks, typically priced below $5, have become a popular choice for day traders due to their potential for rapid gains. These stocks can offer market-beating returns in a short period, making them attractive for those looking for quick profits.

Best Penny Stocks To Buy Now? 3 Under $1 To Watch

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced a collaboration with NVIDIA to accelerate the development of Asensus's Intelligent Surgical Unit™ (ISU™) and improve its ability to deliver novel clinical intelligence to surgeons.

Asensus Surgical Announces Collaboration with NVIDIA to Enhance Augmented Intelligence Capabilities of the ISU

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference. The Company's fireside chat will take place on Monday, September 11, 2023 at 3:00 pm Eastern Time.

Asensus Surgical to Participate in the H.C. Wainwright 25th Annual Global Investment Conference and 2023 Cantor Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that First Towakai Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System in their urology and gynecology centers (Urogynecology center) and gastroenterology department.

Asensus Surgical Announces First Towakai Hospital in Japan to Initiate Senhance Surgery Program

Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.

Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line

Asensus Surgical, Inc. (NYSE:ASXC ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Anthony Fernando - President and Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants RK Ramakanth - H.C. Wainwright & Co. Operator Good afternoon, and welcome to the Asensus Surgical Second Quarter 2023 Business and Financial Update Call.

Asensus Surgical, Inc. (ASXC) Q2 2023 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2023 second quarter financial and operating results after the market closes on Thursday, August 10, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 10, 2023

RESEARCH TRIANGLE PARK, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 23,809,524 shares of its common stock and warrants to purchase 23,809,524 shares of common stock in a registered direct offering. The shares of common stock and accompanying warrants are being sold at a combined purchase price of $0.42 per share and accompanying warrant to purchase one share of common stock. The warrants have an exercise price of $0.42 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about July 31, 2023, subject to the satisfaction of customary closing conditions.

Asensus Surgical Announces $10 Million Registered Direct Offering

Senhance® Surgical System to be Exclusively Utilized within the Pediatric Surgery Department Senhance® Surgical System to be Exclusively Utilized within the Pediatric Surgery Department

Asensus Surgical Announces Leading United States-Based Hospital to Initiate Senhance Surgery Program

Asensus Surgical, Inc. (NYSE:ASXC ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Anthony Fernando - President, CEO & Director Shameze Rampertab - EVP & CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Li Chen - H.C. Wainwright & Co. RK Ramakanth - H.C.

Asensus Surgical, Inc. (ASXC) Q1 2023 Earnings Call Transcript

Asensus Surgical (ASXC) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.07 per share a year ago.

Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates

RESEARCH TRIANGLE PARK, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ (PGS), announced today that it plans to release 2023 first quarter financial and operating results after the market closes on Thursday, May 11, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 11, 2023

System to be Utilized by the Second Largest Private Hospital System in Japan System to be Utilized by the Second Largest Private Hospital System in Japan

Asensus Surgical Announces Fukuoka Tokushukai Hospital in Japan to Initiate Senhance Surgery Program

RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright In-Person Bio-Connect Investor Conference. The Company's fireside chat will take place on Tuesday, May 2, 2023 at 11:30 am Eastern Time.

Asensus Surgical to Participate in the H.C. Wainwright In-Person BioConnect Investor Conference

Allarity Therapeutics

INVO Bioscience

Penny stocks under $1 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 Under $0.99 To Watch Now

Senhance Offers the First and Only Digital Laparoscopic Surgery Solution for Pediatric Patients Senhance Offers the First and Only Digital Laparoscopic Surgery Solution for Pediatric Patients

Asensus Surgical Receives FDA 510(k) Clearance For Pediatric Indication for Senhance Surgical System

Adial Pharmaceuticals Inc

Akebia Therapeutics

Borqs Technologies

Blue Star Foods Corp

Kiromic Biopharma

Myomo

Sono Group NV

vTv Therapeutics

Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Hot Penny Stocks Under $1 To Watch This Week

Penny stocks under $1 to watch this week. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1 To Watch This Week

RESEARCH TRIANGLE PARK, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference. The Company's virtual presentation will take place on Monday, March 13 at 2:00 pm Eastern Time.

Asensus Surgical to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q4 Loss, Lags Revenue Estimates

RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™(PGS), today announced its operating and financial results for the fourth quarter and full year 2022.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2022

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and full year 2022 financial and operating results after the market closes on Thursday, March 2, 2023.

Asensus Surgical, Inc. to Release Fourth Quarter and Full Year 2022 Financial and Operating Results on March 2, 2023

Amyris

AMTD International Inc

LM Funding America

Mobilicom 

Sidus Space

Sorrento Therapeutics Inc

Will penny stock news put these on your buy or sell list this week? The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 To Watch Now After Big News

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, is providing this corporate update in conjunction with its previously announced Investor Day, which will be hosted today, beginning at 11:30am EST.

News for Asensus Surgical Stock (ASXC)